Industry Research Reports
Home > Reports > Pharma & Healthcare > Global Sevoflurane Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Sevoflurane Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Pharma & Healthcare
Published Date: 2025-09-11
Pages: 134 Pages
Report ld: 5042038
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Sevoflurane Market Size(US$)
CAGR 2025-2031
3.6%
Market Size,2031
USD 1,527
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 1,234 million
Market Forecast in 2031(Value)
US$ 1,527 million
CAGR
3.6%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Sevoflurane market is projected to grow from US$ 1195 million in 2024 to US$ 1527 million by 2031, at a CAGR of 3.6% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Sevoflurane is a volatile anesthetic commonly used for induction and maintenance of general anesthesia during surgical procedures. It is favored for its rapid onset and offset of action, making it ideal for both adults and pediatric patients. Sevoflurane is typically inhaled and works by depressing the central nervous system, leading to a reversible loss of consciousness and sensation. Its minimal airway irritation and low blood solubility contribute to smoother anesthesia induction and quicker recovery times compared to other anesthetics. Sevoflurane is widely used due to its safety profile and ease of administration.
The key driver for the Sevoflurane market is the increasing number of surgeries worldwide, driven by the aging population and the rising prevalence of chronic conditions requiring surgical intervention. Sevoflurane is highly preferred due to its rapid onset and recovery, making it ideal for both pediatric and adult patients, particularly in outpatient surgeries. Technological advancements in anesthesia delivery systems and the growing demand for minimally invasive procedures have also contributed to the rising adoption of Sevoflurane in clinical settings. Furthermore, the safety and effectiveness of Sevoflurane in maintaining stable cardiovascular function during anesthesia have enhanced its demand.
One of the main challenges in the Sevoflurane market is its high cost compared to other anesthetic agents, which can limit its accessibility in low- and middle-income regions. Additionally, environmental concerns regarding the use of volatile anesthetics like Sevoflurane, which contribute to greenhouse gas emissions, have led to increased scrutiny and calls for more sustainable alternatives. Regulatory restrictions and the availability of generic alternatives may further impact the market growth, as healthcare providers seek more cost-effective or environmentally friendly options.
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Sevoflurane market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Hengrui
- Baxter
- Maruishi
- AbbVie
- Piramal
- Viatris
- PT Novell Pharmaceutical
- Lunan Pharma
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Generic Drug
- Original Drug
Segment by Application
- Hospital
- Clinics
- Other
CHAPTER OUTLINE
Chapter 1: Defines the Sevoflurane study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Sevoflurane: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Sevoflurane Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Generic Drug
1.2.3 Original Drug
1.3 Market Segmentation by Application
1.3.1 Global Sevoflurane Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Sevoflurane Revenue Estimates and Forecasts 2020-2031
2.2 Global Sevoflurane Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Sevoflurane Sales Estimates and Forecasts 2020-2031
2.4 Global Sevoflurane Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Sevoflurane Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Sevoflurane Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Generic Drug Market Size by Manufacturers
3.5.2 Original Drug Market Size by Manufacturers
3.6 Global Sevoflurane Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Sevoflurane Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Sevoflurane Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Sevoflurane Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Sevoflurane Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Sevoflurane Sales and Revenue by Type (2020-2031)
6.4 North America Sevoflurane Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Sevoflurane Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Sevoflurane Sales and Revenue by Type (2020-2031)
7.4 Europe Sevoflurane Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Sevoflurane Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Sevoflurane Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Sevoflurane Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Sevoflurane Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Sevoflurane Sales and Revenue by Type (2020-2031)
9.4 Central and South America Sevoflurane Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Sevoflurane Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Sevoflurane Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Sevoflurane Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Sevoflurane Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Hengrui
11.1.1 Hengrui Corporation Information
11.1.2 Hengrui Business Overview
11.1.3 Hengrui Sevoflurane Product Models, Descriptions and Specifications
11.1.4 Hengrui Sevoflurane Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Hengrui Sevoflurane Sales by Product in 2024
11.1.6 Hengrui Sevoflurane Sales by Application in 2024
11.1.7 Hengrui Sevoflurane Sales by Geographic Area in 2024
11.1.8 Hengrui Sevoflurane SWOT Analysis
11.1.9 Hengrui Recent Developments
11.2 Baxter
11.2.1 Baxter Corporation Information
11.2.2 Baxter Business Overview
11.2.3 Baxter Sevoflurane Product Models, Descriptions and Specifications
11.2.4 Baxter Sevoflurane Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Baxter Sevoflurane Sales by Product in 2024
11.2.6 Baxter Sevoflurane Sales by Application in 2024
11.2.7 Baxter Sevoflurane Sales by Geographic Area in 2024
11.2.8 Baxter Sevoflurane SWOT Analysis
11.2.9 Baxter Recent Developments
11.3 Maruishi
11.3.1 Maruishi Corporation Information
11.3.2 Maruishi Business Overview
11.3.3 Maruishi Sevoflurane Product Models, Descriptions and Specifications
11.3.4 Maruishi Sevoflurane Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Maruishi Sevoflurane Sales by Product in 2024
11.3.6 Maruishi Sevoflurane Sales by Application in 2024
11.3.7 Maruishi Sevoflurane Sales by Geographic Area in 2024
11.3.8 Maruishi Sevoflurane SWOT Analysis
11.3.9 Maruishi Recent Developments
11.4 AbbVie
11.4.1 AbbVie Corporation Information
11.4.2 AbbVie Business Overview
11.4.3 AbbVie Sevoflurane Product Models, Descriptions and Specifications
11.4.4 AbbVie Sevoflurane Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 AbbVie Sevoflurane Sales by Product in 2024
11.4.6 AbbVie Sevoflurane Sales by Application in 2024
11.4.7 AbbVie Sevoflurane Sales by Geographic Area in 2024
11.4.8 AbbVie Sevoflurane SWOT Analysis
11.4.9 AbbVie Recent Developments
11.5 Piramal
11.5.1 Piramal Corporation Information
11.5.2 Piramal Business Overview
11.5.3 Piramal Sevoflurane Product Models, Descriptions and Specifications
11.5.4 Piramal Sevoflurane Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Piramal Sevoflurane Sales by Product in 2024
11.5.6 Piramal Sevoflurane Sales by Application in 2024
11.5.7 Piramal Sevoflurane Sales by Geographic Area in 2024
11.5.8 Piramal Sevoflurane SWOT Analysis
11.5.9 Piramal Recent Developments
11.6 Viatris
11.6.1 Viatris Corporation Information
11.6.2 Viatris Business Overview
11.6.3 Viatris Sevoflurane Product Models, Descriptions and Specifications
11.6.4 Viatris Sevoflurane Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Viatris Recent Developments
11.7 PT Novell Pharmaceutical
11.7.1 PT Novell Pharmaceutical Corporation Information
11.7.2 PT Novell Pharmaceutical Business Overview
11.7.3 PT Novell Pharmaceutical Sevoflurane Product Models, Descriptions and Specifications
11.7.4 PT Novell Pharmaceutical Sevoflurane Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 PT Novell Pharmaceutical Recent Developments
11.8 Lunan Pharma
11.8.1 Lunan Pharma Corporation Information
11.8.2 Lunan Pharma Business Overview
11.8.3 Lunan Pharma Sevoflurane Product Models, Descriptions and Specifications
11.8.4 Lunan Pharma Sevoflurane Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Lunan Pharma Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Sevoflurane Industry Chain
12.2 Sevoflurane Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Sevoflurane Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Sevoflurane Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Sevoflurane Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Sevoflurane Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Sevoflurane Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Sevoflurane Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Sevoflurane Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Sevoflurane Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Sevoflurane Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Sevoflurane Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Sevoflurane Sales by Region (2020-2025) & (K Units)
Table 8. Global Sevoflurane Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Sevoflurane Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Sevoflurane Sales Share by Manufacturers (2020-2025)
Table 12. Global Sevoflurane Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Sevoflurane Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Sevoflurane by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sevoflurane as of 2024)
Table 16. Global Sevoflurane Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Sevoflurane Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Sevoflurane Manufacturing Base and Headquarters
Table 19. Global Sevoflurane Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Sevoflurane Sales by Type (2020-2025) & (K Units)
Table 23. Global Sevoflurane Sales by Type (2026-2031) & (K Units)
Table 24. Global Sevoflurane Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Sevoflurane Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Sevoflurane ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Sevoflurane Sales by Application (2020-2025) & (K Units)
Table 29. Global Sevoflurane Sales by Application (2026-2031) & (K Units)
Table 30. Sevoflurane High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Sevoflurane Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Sevoflurane Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Sevoflurane ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Sevoflurane Growth Accelerators and Market Barriers
Table 37. North America Sevoflurane Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Sevoflurane Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Sevoflurane Growth Accelerators and Market Barriers
Table 40. Europe Sevoflurane Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Sevoflurane Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Sevoflurane Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Sevoflurane Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Sevoflurane Growth Accelerators and Market Barriers
Table 45. Southeast Asia Sevoflurane Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Sevoflurane Investment Opportunities and Key Challenges
Table 47. Central and South America Sevoflurane Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Sevoflurane Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Sevoflurane Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Hengrui Corporation Information
Table 51. Hengrui Description and Major Businesses
Table 52. Hengrui Product Models, Descriptions and Specifications
Table 53. Hengrui Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Hengrui Sales Value Proportion by Product in 2024
Table 55. Hengrui Sales Value Proportion by Application in 2024
Table 56. Hengrui Sales Value Proportion by Geographic Area in 2024
Table 57. Hengrui Sevoflurane SWOT Analysis
Table 58. Hengrui Recent Developments
Table 59. Baxter Corporation Information
Table 60. Baxter Description and Major Businesses
Table 61. Baxter Product Models, Descriptions and Specifications
Table 62. Baxter Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Baxter Sales Value Proportion by Product in 2024
Table 64. Baxter Sales Value Proportion by Application in 2024
Table 65. Baxter Sales Value Proportion by Geographic Area in 2024
Table 66. Baxter Sevoflurane SWOT Analysis
Table 67. Baxter Recent Developments
Table 68. Maruishi Corporation Information
Table 69. Maruishi Description and Major Businesses
Table 70. Maruishi Product Models, Descriptions and Specifications
Table 71. Maruishi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Maruishi Sales Value Proportion by Product in 2024
Table 73. Maruishi Sales Value Proportion by Application in 2024
Table 74. Maruishi Sales Value Proportion by Geographic Area in 2024
Table 75. Maruishi Sevoflurane SWOT Analysis
Table 76. Maruishi Recent Developments
Table 77. AbbVie Corporation Information
Table 78. AbbVie Description and Major Businesses
Table 79. AbbVie Product Models, Descriptions and Specifications
Table 80. AbbVie Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. AbbVie Sales Value Proportion by Product in 2024
Table 82. AbbVie Sales Value Proportion by Application in 2024
Table 83. AbbVie Sales Value Proportion by Geographic Area in 2024
Table 84. AbbVie Sevoflurane SWOT Analysis
Table 85. AbbVie Recent Developments
Table 86. Piramal Corporation Information
Table 87. Piramal Description and Major Businesses
Table 88. Piramal Product Models, Descriptions and Specifications
Table 89. Piramal Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Piramal Sales Value Proportion by Product in 2024
Table 91. Piramal Sales Value Proportion by Application in 2024
Table 92. Piramal Sales Value Proportion by Geographic Area in 2024
Table 93. Piramal Sevoflurane SWOT Analysis
Table 94. Piramal Recent Developments
Table 95. Viatris Corporation Information
Table 96. Viatris Description and Major Businesses
Table 97. Viatris Product Models, Descriptions and Specifications
Table 98. Viatris Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Viatris Recent Developments
Table 100. PT Novell Pharmaceutical Corporation Information
Table 101. PT Novell Pharmaceutical Description and Major Businesses
Table 102. PT Novell Pharmaceutical Product Models, Descriptions and Specifications
Table 103. PT Novell Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. PT Novell Pharmaceutical Recent Developments
Table 105. Lunan Pharma Corporation Information
Table 106. Lunan Pharma Description and Major Businesses
Table 107. Lunan Pharma Product Models, Descriptions and Specifications
Table 108. Lunan Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Lunan Pharma Recent Developments
Table 110. Key Raw Materials Distribution
Table 111. Raw Materials Key Suppliers
Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 113. Milestones in Production Technology Evolution
Table 114. Distributors List
Table 115. Market Trends and Market Evolution
Table 116. Market Drivers and Opportunities
Table 117. Market Challenges, Risks, and Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Sevoflurane Product Picture
Figure 2. Global Sevoflurane Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Generic Drug Product Picture
Figure 4. Original Drug Product Picture
Figure 5. Global Sevoflurane Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital
Figure 7. Clinics
Figure 8. Other
Figure 9. Sevoflurane Report Years Considered
Figure 10. Global Sevoflurane Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 12. Global Sevoflurane Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Sevoflurane Revenue Market Share by Region (2020-2031)
Figure 14. Global Sevoflurane Sales (2020-2031) & (K Units)
Figure 15. Global Sevoflurane Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Sevoflurane Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Sevoflurane Sales Volume Market Share in 2024
Figure 18. Global Sevoflurane Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Generic Drug Revenue Market Share by Manufacturer in 2024
Figure 21. Original Drug Revenue Market Share by Manufacturer in 2024
Figure 22. Global Sevoflurane Sales Market Share by Type (2020-2031)
Figure 23. Global Sevoflurane Revenue Market Share by Type (2020-2031)
Figure 24. Global Sevoflurane Sales Market Share by Application (2020-2031)
Figure 25. Global Sevoflurane Revenue Market Share by Application (2020-2031)
Figure 26. North America Sevoflurane Sales YoY (2020-2031) & (K Units)
Figure 27. North America Sevoflurane Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Sevoflurane Sales Revenue (US$ Million) in 2024
Figure 29. North America Sevoflurane Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America Sevoflurane Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Sevoflurane Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America Sevoflurane Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Sevoflurane Sales YoY (2020-2031) & (K Units)
Figure 37. Europe Sevoflurane Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Sevoflurane Sales Revenue (US$ Million) in 2024
Figure 39. Europe Sevoflurane Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe Sevoflurane Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Sevoflurane Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe Sevoflurane Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 44. France Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Sevoflurane Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific Sevoflurane Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Sevoflurane Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Sevoflurane Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific Sevoflurane Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Sevoflurane Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific Sevoflurane Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 59. India Sevoflurane Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Sevoflurane Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America Sevoflurane Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Sevoflurane Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Sevoflurane Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America Sevoflurane Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Sevoflurane Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America Sevoflurane Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Sevoflurane Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Sevoflurane Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Sevoflurane Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa Sevoflurane Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Sevoflurane Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Sevoflurane Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America Sevoflurane Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Sevoflurane Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa Sevoflurane Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Sevoflurane Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Sevoflurane Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Sevoflurane Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Sevoflurane Revenue (2020-2025) & (US$ Million)
Figure 80. Sevoflurane Industry Chain Mapping
Figure 81. Regional Sevoflurane Manufacturing Base Distribution (%)
Figure 82. Global Sevoflurane Production Market Share by Region (2020-2031)
Figure 83. Sevoflurane Production Process
Figure 84. Regional Sevoflurane Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of Sevoflurane in 2031?
The global market size of Sevoflurane in 2031 was 1527 Million USD.
What is the annual compound growth rate of the global Sevoflurane market size from 2025 to 2031?
Which companies rank high in the global Sevoflurane market?
What was the global market size of Sevoflurane in 2025?
Which region is expected to have the highest market share?
Related Reports
Global Sevoflurane Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Sevoflurane market size was US$ 1234 million in 2025 and is forecast to reach a readjusted size of US$ 1577 million by 2032 with a CAGR of 3.6% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 78
USD 4250.00
(Single User License)
Global Sevoflurane Market Research Report 2026
The global Sevoflurane market was valued at US$ 1234 million in 2025 and is anticipated to reach US$ 1577 million by 2032, at a CAGR of 3.6% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 113
USD 2900.00
(Single User License)
Sevoflurane- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Sevoflurane was estimated to be worth US$ 1234 million in 2025 and is projected to reach US$ 1577 million, growing at a CAGR of 3.6% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 94
USD 3950.00
(Single User License)
Global Sevoflurane Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Sevoflurane was estimated to be worth US$ 1195 million and is forecast to reach approximately US$ 1527 million by 2031 with a CAGR of 3.6% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 140
USD 5900.00
(Single User License)
Global Sevoflurane Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Sevoflurane market size was US$ 1195 million in 2024 and is forecast to a readjusted size of US$ 1527 million by 2031 with a CAGR of 3.6% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 78
USD 4250.00
(Single User License)
Sevoflurane- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Sevoflurane was estimated to be worth US$ 1195 million in 2024 and is forecast to a readjusted size of US$ 1527 million by 2031 with a CAGR of 3.6% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 93
USD 3950.00
(Single User License)
Global Sevoflurane Market Research Report 2025
The global market for Sevoflurane was valued at US$ 1195 million in the year 2024 and is projected to reach a revised size of US$ 1527 million by 2031, growing at a CAGR of 3.6% during the forecast period.
Published Date: 2025-01-16
Pages: 84
USD 2900.00
(Single User License)
Global and China Sevoflurane Market Report & Forecast 2024-2030
Sevoflurane is a volatile anesthetic commonly used for induction and maintenance of general anesthesia during surgical procedures. It is favored for its rapid onset and offset of action, making it ideal for both adults and pediatric patients. Sevoflurane is typically inhaled and works by depressing the central nervous system, leading to a reversible loss of consciousness and sensation. Its minimal airway irritation and low blood solubility contribute to smoother anesthesia induction and quicker recovery times compared to other anesthetics. Sevoflurane is widely used due to its safety profile and ease of administration.
Published Date: 2024-09-11
Pages: 105
USD 4350.00
(Single User License)
Sevoflurane- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sevoflurane is a volatile anesthetic commonly used for induction and maintenance of general anesthesia during surgical procedures. It is favored for its rapid onset and offset of action, making it ideal for both adults and pediatric patients. Sevoflurane is typically inhaled and works by depressing the central nervous system, leading to a reversible loss of consciousness and sensation. Its minimal airway irritation and low blood solubility contribute to smoother anesthesia induction and quicker recovery times compared to other anesthetics. Sevoflurane is widely used due to its safety profile and ease of administration.
Published Date: 2024-09-11
Pages: 107
USD 3950.00
(Single User License)
Global Sevoflurane Market Insights, Forecast to 2030
Sevoflurane is a volatile anesthetic commonly used for induction and maintenance of general anesthesia during surgical procedures. It is favored for its rapid onset and offset of action, making it ideal for both adults and pediatric patients. Sevoflurane is typically inhaled and works by depressing the central nervous system, leading to a reversible loss of consciousness and sensation. Its minimal airway irritation and low blood solubility contribute to smoother anesthesia induction and quicker recovery times compared to other anesthetics. Sevoflurane is widely used due to its safety profile and ease of administration.
Published Date: 2024-09-11
Pages: 135
USD 4900.00
(Single User License)
Global Sevoflurane Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Sevoflurane market size was US$ 1234 million in 2025 and is forecast to reach a readjusted size of US$ 1577 million by 2032 with a CAGR of 3.6% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 78
USD 4250.00 (Single User License)Global Sevoflurane Market Research Report 2026
The global Sevoflurane market was valued at US$ 1234 million in 2025 and is anticipated to reach US$ 1577 million by 2032, at a CAGR of 3.6% from 2026 to 2032.
Published: 2026-01-04
Pages: 113
USD 2900.00 (Single User License)Sevoflurane- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Sevoflurane was estimated to be worth US$ 1234 million in 2025 and is projected to reach US$ 1577 million, growing at a CAGR of 3.6% from 2026 to 2032.
Published: 2026-01-04
Pages: 94
USD 3950.00 (Single User License)Global Sevoflurane Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Sevoflurane was estimated to be worth US$ 1195 million and is forecast to reach approximately US$ 1527 million by 2031 with a CAGR of 3.6% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 140
USD 5900.00 (Single User License)Global Sevoflurane Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Sevoflurane market size was US$ 1195 million in 2024 and is forecast to a readjusted size of US$ 1527 million by 2031 with a CAGR of 3.6% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 78
USD 4250.00 (Single User License)Sevoflurane- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Sevoflurane was estimated to be worth US$ 1195 million in 2024 and is forecast to a readjusted size of US$ 1527 million by 2031 with a CAGR of 3.6% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 93
USD 3950.00 (Single User License)Global Sevoflurane Market Research Report 2025
The global market for Sevoflurane was valued at US$ 1195 million in the year 2024 and is projected to reach a revised size of US$ 1527 million by 2031, growing at a CAGR of 3.6% during the forecast period.
Published: 2025-01-16
Pages: 84
USD 2900.00 (Single User License)Global and China Sevoflurane Market Report & Forecast 2024-2030
Sevoflurane is a volatile anesthetic commonly used for induction and maintenance of general anesthesia during surgical procedures. It is favored for its rapid onset and offset of action, making it ideal for both adults and pediatric patients. Sevoflurane is typically inhaled and works by depressing the central nervous system, leading to a reversible loss of consciousness and sensation. Its minimal airway irritation and low blood solubility contribute to smoother anesthesia induction and quicker recovery times compared to other anesthetics. Sevoflurane is widely used due to its safety profile and ease of administration.
Published: 2024-09-11
Pages: 105
USD 4350.00 (Single User License)Sevoflurane- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sevoflurane is a volatile anesthetic commonly used for induction and maintenance of general anesthesia during surgical procedures. It is favored for its rapid onset and offset of action, making it ideal for both adults and pediatric patients. Sevoflurane is typically inhaled and works by depressing the central nervous system, leading to a reversible loss of consciousness and sensation. Its minimal airway irritation and low blood solubility contribute to smoother anesthesia induction and quicker recovery times compared to other anesthetics. Sevoflurane is widely used due to its safety profile and ease of administration.
Published: 2024-09-11
Pages: 107
USD 3950.00 (Single User License)Global Sevoflurane Market Insights, Forecast to 2030
Sevoflurane is a volatile anesthetic commonly used for induction and maintenance of general anesthesia during surgical procedures. It is favored for its rapid onset and offset of action, making it ideal for both adults and pediatric patients. Sevoflurane is typically inhaled and works by depressing the central nervous system, leading to a reversible loss of consciousness and sensation. Its minimal airway irritation and low blood solubility contribute to smoother anesthesia induction and quicker recovery times compared to other anesthetics. Sevoflurane is widely used due to its safety profile and ease of administration.
Published: 2024-09-11
Pages: 135
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now